FDA Eyes Pill Pipelines to Sniff Out Fake Meds
Published Date: 5/1/2025
Notice
Summary
The FDA is asking for approval to collect info about how medicines move through the supply chain to keep drugs safe and real. This affects drug makers, distributors, and pharmacies who must share certain details to track medicines better. The goal? Make sure your meds are legit without causing big delays or extra costs.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Supply-Chain Data Sharing Duty
If you run or work for a drug maker, distributor, or pharmacy, you must share certain details about how medicines move through the supply chain so drugs can be tracked better. The FDA is seeking approval to collect that information under the Paperwork Reduction Act.
Stronger Assurance Medicines Are Legit
You will benefit from better tracking of how medicines move through the supply chain because the FDA is collecting information to keep drugs safe and real. The agency says the goal is to ensure your medicines are legitimate while not causing big delays or extra costs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-07568, Agency Information Collection Activities; Proposed Collection; Comment Request; Public Health Service Guideline on Infectious Disease Issues in Xenotransplantation
The FDA wants your thoughts on collecting info about infectious disease risks in xenotransplantation—where animal organs might be used in humans. This affects researchers and healthcare folks working with these transplants. They’re asking for comments within 60 days to keep things safe and smooth, with no new costs expected.
Next: 2025-07571, Importer of Controlled Substances Application: Unither Manufacturing LLC
Unither Manufacturing LLC wants to get official permission to import certain controlled substances. This means they’ll be allowed to bring in specific drugs that are carefully regulated. If approved, this could affect companies and regulators keeping an eye on drug imports, with no immediate cost or timing changes announced.